Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News IN8BIO, Inc. INAB

Healthcare Biotechnology
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400,... see more

Recent & Breaking News (NDAQ:INAB)

IN8bio to Present at Biotech Showcase 2025 in San Francisco

GlobeNewswire 3 days ago

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

GlobeNewswire December 10, 2024

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

GlobeNewswire December 2, 2024

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

GlobeNewswire November 25, 2024

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

GlobeNewswire November 12, 2024

IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

GlobeNewswire November 12, 2024

IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting

GlobeNewswire November 5, 2024

IN8bio Announces Pricing of $12.4 Million Private Placement

GlobeNewswire October 1, 2024

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

GlobeNewswire September 4, 2024

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire August 29, 2024

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

GlobeNewswire August 12, 2024

IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

GlobeNewswire August 8, 2024

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

GlobeNewswire June 24, 2024

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

GlobeNewswire June 13, 2024

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

GlobeNewswire June 3, 2024

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

GlobeNewswire May 24, 2024

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

GlobeNewswire May 23, 2024

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

GlobeNewswire May 14, 2024

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

GlobeNewswire May 13, 2024

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

GlobeNewswire May 9, 2024